6,790 AbbVie Inc. $ABBV Shares Sold by AMF Tjanstepension AB

AMF Tjanstepension AB cut its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 22.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,119 shares of the company's stock after selling 6,790 shares during the quarter. AMF Tjanstepension AB's holdings in AbbVie were worth $6,309,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. E. Ohman J or Asset Management AB boosted its holdings in AbbVie by 2.1% in the 3rd quarter. E. Ohman J or Asset Management AB now owns 63,662 shares of the company's stock worth $16,653,000 after buying an additional 1,300 shares during the period. McCarley & Cook Financial Planners grew its stake in AbbVie by 510.7% in the 3rd quarter. McCarley & Cook Financial Planners now owns 2,394 shares of the company's stock valued at $626,000 after buying an additional 2,002 shares in the last quarter. Courage Miller Partners LLC purchased a new position in AbbVie in the 3rd quarter valued at approximately $207,000. Crescent Grove Advisors LLC raised its holdings in AbbVie by 62.4% during the 3rd quarter. Crescent Grove Advisors LLC now owns 7,967 shares of the company's stock valued at $2,084,000 after acquiring an additional 3,061 shares during the period. Finally, Obermeyer Wealth Partners raised its holdings in AbbVie by 0.7% during the 3rd quarter. Obermeyer Wealth Partners now owns 10,908 shares of the company's stock valued at $2,853,000 after acquiring an additional 76 shares during the period. Hedge funds and other institutional investors own 70.23% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Morgan Stanley increased their target price on AbbVie from $296.00 to $310.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 7th. Weiss Ratings upgraded AbbVie from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, October 8th. Citigroup boosted their price objective on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research note on Wednesday, July 15th. Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 5th. Finally, HSBC increased their price objective on AbbVie from $300.00 to $315.00 and gave the stock a "buy" rating in a report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $278.07.

AbbVie Trading Down 0.1%

ABBV stock opened at $284.59 on Friday. The company's 50 day moving average is $265.60 and its 200 day moving average is $241.46. The stock has a market cap of $502.80 billion, a price-to-earnings ratio of 80.39, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period last year, the firm posted $2.97 earnings per share. AbbVie's quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 13.94 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie's dividend payout ratio is presently 195.48%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by insiders.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Lutikizumab met its Phase 3 INTREPID trial objectives. AbbVie reported that the experimental treatment for moderate-to-severe hidradenitis suppurativa achieved its primary HiSCR75 endpoint and eight ranked secondary endpoints, including reduced skin pain and fewer disease flares. The drug was generally well tolerated, with no new safety concerns. AbbVie INTREPID Phase 3 results
• Positive Sentiment: Investors continue to see potential in AbbVie’s broader immunology pipeline. Phase 2a results for a possible Skyrizi successor in Crohn’s disease and a promising eczema candidate could help support growth as AbbVie prepares for future patent expirations. Great News for AbbVie Stock Investors
• Neutral Sentiment: The INTREPID results were positive but commercially ambiguous. Although lutikizumab reduced abscess burden and met prespecified endpoints, the magnitude of benefit reportedly fell short of analyst benchmarks. That raises questions about the drug’s competitive positioning and potential sales opportunity, despite the successful trial. AbbVie skin disease drug Phase 3 results
• Negative Sentiment: Analysts characterized the efficacy as underwhelming. Lutikizumab beat placebo by roughly eight percentage points on its main measure, but the result lagged some efficacy benchmarks. Shares of rival MoonLake rose on expectations that its competing hidradenitis suppurativa therapy may remain better positioned. MoonLake reaction to AbbVie trial data
• Negative Sentiment: AbbVie halted an early-stage liver-cancer combination study. The discontinued Phase 1b trial removes one development program from the oncology pipeline, although its financial impact is likely limited compared with the company’s late-stage immunology portfolio. AbbVie liver cancer trial update

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.